Tissue based biomarkers analysis from the ASPEN trial

The Pathway of Belzutifan, from clinical trials to clinical practice

Expert Perspectives - Dr. Nicholas Vogelzang

Resource-efficient pooled sequencing expands translational impact

TKIs Beyond Second-Line Therapy

What morphology can teach us about renal cell carcinoma clonal evolution

Latest Issue

Original Contribution

Tissue based biomarkers in non-clear cell RCC: Correlative analysis from the ASPEN clinical trial

Susan Halabi, Qian Yang, Andrea Carmack, Andrew J. Armstrong MD et al.

Abstract
We enrolled 108 patients in ASPEN, an international randomized open-label phase 2 trial of patients with metastatic papillary, chromophobe, or unclassified NC-RCC treated with the mTOR inhibitor everolimus (n=57) or the vascular endothelial growth factor (VEGF) receptor inhibitor sunitinib (n=51), stratified by MSKCC risk and histology. ...........Show full content
Expert Q&A

The Pathway of Belzutifan, from clinical trials to clinical practice:

A conversation with Dr. Ramaprasad Srinivasan, MD, PhD

Abstract
"I believe that belzutifan will play an important role in the management of certain VHL patients and should be used judiciously along with surgery as part of a multidisciplinary strategy."...........Show full content
Review Article

The Current and Evolving Therapeutic Paradigm in the Management of Metastatic Renal Cell Carcinoma

Thomas Hutson, MD, Robert A. Figlin, MD, FACP

Abstract
There is an unmet need for developing novel biomarkers predictive of treatment response, optimizing treatment selection, and also improving strategies to overcome therapeutic resistance in heterogenous RCC tumors. Herein, we outline currently available first- and later-lines treatment strategies, unprecedented changes, and also discuss challenges in the treatment landscape of RCC.
Expert Perspectives

Nicholas J. Vogelzang, MD, FASCO, FACP

Dr. Vogelzang

Abstract
"Now we have ten plus drugs, that's indeed an embarrassment of riches. As a matter of fact, we don't even quite know how best to sequence."...........Show full content
KCJ Editor's Memo

Robert A. Figlin MD

Novel Combination Therapies Shake Up the Spectrum of Renal Cancer Treatment.....Show full content
Medical Intelligence

Nicholas J. Vogelzang, MD, FASCO, FACP

Dr. Vogelzang

" Newsworthy, late-breaking information from Web-based sources, professional societies, and government agencies"...........Show full content
Original Contribution

Resource-efficient pooled sequencing expands translational impact in solid tumors

Renzo G. DiNatale et al.

Abstract
Intratumoral genetic heterogeneity (ITH) poses a significant challenge to utilizing sequencing for decision making in the management of cancer. Our findings demonstrate that pooled DNA sequencing strategies are a cost-effective alternative to address intrinsic genetic heterogeneity in clinical settings...........Show full content
Roundtable Monograph

Changes, Challenges and Opportunities in Cancer Care During the COVID-19 Era and Beyond

Robert J. Motzer, MD, Eric A. Jonasch, MD,Bradley A. McGregor, MD, Robert A. Figlin, MD, FACP

Abstract
In this roundtable discussion, nation's leading cancer experts from across the country share their perspectives on current changes, challenges and opportunities for delivering cancer care during the COVID-19 era. The roundtable panel examines long-term implications of the pandemic on the management and treatment of cancer especially focusing on significant issues in patient safety, toxicities associated with the use of immunotherapy, COVID-19 vaccination, and clinical trial designs. In this discussion, experts also brainstorm a range of recommendations focusing especially on how the cancer community can capitalize on lessons learned from the pandemic to develop creative approaches that can be taken forward........Show full content
Review

Renal Cell Carcinoma Associated with Germline Mutations in the Krebs Cycle

Eric Lu, Brian Shuch, Alexandra Drakaki

Abstract
Germline mutations in the fumarate hydratase (FH) and succinate dehydrogenase (SDH) genes lead to hereditary leiomyomatosis and RCC (HLRCC) and hereditary paraganglioma and pheochromocytoma, respectively. The renal cell carcinomas that arise in these conditions are characterized by dysregulated Krebs cycles, accumulation of oncometabolites, downstream changes in gene expression, and epigenetic modifications that carry unique therapeutic implications. In this review, we evaluate the current literature on these tumors, including the epidemiology, clinical course, screening guidelines, and management of localized and metastatic disease.Show full content
Editor's Memo

Robert A. Figlin MD

ASCO21 Kidney Cancer Roundup
The COVID-19 pandemic has exposed fundamental disparities in the provision of health care across our nation and exacerbated the differences in health outcomes associated with race, socioeconomic and other demographic factors. A silver lining however is that pandemic precarity has inspired tremendous scientific collaboration among clinicians, researchers, and key opinion leaders.....Show full content
Medical Intelligence

Newsworthy, late-breaking information from Web-based sources, professional societies, and government agencies ...Show full content
KCJ Journal Club

Essential Peer-Reviewed Reading in Kidney Cancer

The peer-reviewed articles summarized in this section were selected by the Editor-in-Chief, Robert A. Figlin, MD, for their timeliness, importance, relevance, and potential impact on clinical practice or translational research ...Show full content

KCJ SUPPLEMENT - ASCO21 Special

ASCO21 Session

ASCO21 - RECOMMENDED ABSTRACTS IN KIDNEY CANCER

Robert A. Figlin, MD

Abstract

These recommended abstracts have been selected by Robert A. Figlin, MD, Editor-in- Chief. The chosen abstracts provided here highlight some of the most important trends in ongoing trials and reflect the foremost research and strategies from latest clinical trials that impact the current standard of care in renal cancer............Show full content

ASCO21-Abstracts Robert Figlin, MD

Important Articles from Archives

KCJ

KCJ

Vol 19, Issue 1
JUNE 2021

Table of content

Tweets by KidneyCancerJ